Revenue Breakdown
Composition ()
No data
Revenue Streams
Adaptive Biotechnologies Corp (ADPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MRD revenue, accounting for 60.4% of total sales, equivalent to $56.79M. Another important revenue stream is Immune meidicine revenue. Understanding this composition is critical for investors evaluating how ADPT navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Adaptive Biotechnologies Corp maintains a gross margin of 73.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.82%, while the net margin is -18.94%. These profitability ratios, combined with a Return on Equity (ROE) of -28.23%, provide a clear picture of how effectively ADPT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ADPT competes directly with industry leaders such as IMNM and DYN. With a market capitalization of $2.48B, it holds a leading position in the sector. When comparing efficiency, ADPT's gross margin of 73.98% stands against IMNM's 100.00% and DYN's N/A. Such benchmarking helps identify whether Adaptive Biotechnologies Corp is trading at a premium or discount relative to its financial performance.
